Cel-sci's multikine phase 3 cancer study shows 43% survival extension

Vienna, va.--(business wire)---- $cvm #echno--cel-sci's multikine phase 3 cancer study shows 43% survival extension.
CVM Ratings Summary
CVM Quant Ranking